Nov 13,2015

Tandem Diabetes Care to Present at the 27th Annual Piper Jaffray Healthcare Conference

Tandem Diabetes Care®, Inc. (NASDAQ:TNDM), a medical device company and manufacturer of the t:slim®, t:flex® and t:slim G4™ Insulin Pumps, today announced that Kim Blickenstaff, president and CEO, will present a company update at the 27th Annual Piper Jaffray Healthcare Conference in New York, NY. The presentation will take place on Tuesday, December 1, 2015 at 9:00am Eastern Time (6:00am Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 13,2015

Insulet Corporation Recognizes National Diabetes Awareness Month at NASDAQ Stock Market Opening Bell Ceremony

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that Patrick Sullivan, Insulet's President and Chief Executive Officer, will preside over the NASDAQ Stock Market Opening Bell Ceremony on November 16, 2015, in celebration of National Diabetes Awareness Month. In his remarks, Mr. Sullivan will highlight the important role of the Company's OmniPod System in helping those with diabetes manage their condition and achieve improved quality of life.

View Analyst & Ambassador Comments
Go to original news
Nov 13,2015

Insulet Corporation to Present at Upcoming Investor Conferences

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that management will present at the following upcoming investor conferences in New York City, New York: The 2015 Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 19, 2015 at 1:30pm (Eastern Time). The 27th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 11:00am (Eastern Time). The Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 1:00pm (Eastern Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 13,2015

LabStyle Innovations Reports Third Quarter 2015 Results

LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today reported financial and operational results for the three months ended September 30, 2015 and provided an outlook for the coming quarters. LabStyle's billings for the third quarter of 2015 amounted to approximately $292,000 compared to approximately $250,000 in the second quarter of 2015 and approximately $141,000 in the first quarter of 2015. LabStyle's revenues for the third quarter of 2015 amounted to approximately $273,000 compared to approximately $175,000 in the second quarter of 2015 and $67,000 in the first quarter of 2015.

View Analyst & Ambassador Comments
Go to original news
Nov 16,2015

LabStyle Innovations' Leadership in Mobile Health Featured in Facebook Case Study

LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced that Facebook (NASDAQ:FB) published a case study about the Company's social media marketing campaign for the Dario on Facebook for Business' Success Story series. To view the case study visit: https://www.facebook.com/business/success/dario

View Analyst & Ambassador Comments
Go to original news
Nov 17,2015

Tandem Diabetes Care Announces Retirement of Board Chairman Lonnie Smith; Dick Allen Appointed as Successor Chairman

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps, today announced that Chairman of the Board Lonnie Smith is retiring from the Company's board of directors effective December 31, 2015. Director Dick Allen has been elected to succeed him as Chairman.

View Analyst & Ambassador Comments
Go to original news
Nov 19,2015

LabStyle Innovations Closes $2.3 Million Round of Investment From Existing Shareholders and Private Investors

LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced it has closed on an offering raising approximately $2.3 million in proceeds through the private placement of 7,648,267 shares of Common Stock and warrants to purchase 7,648,267 shares of Common Stock with existing shareholders and private investors including a member of the Company's board of directors, employees and a Dario distributor.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Nov 23,2015

"Brighter One" becomes "Actiste™"

The development of Brighter's integrated tool for insulin-treated diabetics has exceeded expectations. The focus groups that the company has conducted show very positive results. In connection with this, Brighter has also decided that the new brand Actiste will replace the former name Brighter One.

PRODUCT

#insulin pen

#bgm

View Analyst & Ambassador Comments
Go to original news
Dec 17,2015

WellDoc raises $22M for its BlueStar mobile-enabled diabetes management offering

Baltimore, Maryland-based WellDoc has raised $22 million in a round led by Samsung Ventures and Merck Global Health Innovation (GHI) Fund with participation from Adage Capital Management, Excel Venture Management, Alexandria Venture Investments and Hudson River Capital Partners.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Dec 02,2015

Nemaura Medical Announces Joint Venture for European Launch of sugarBEAT® System

Nemaura Medical Inc., a medical device company developing a minimally invasive wireless continuous glucose monitoring system known as sugarBEAT, announced today that it has entered into an equal Joint Venture agreement with DBJ Jersey to market the sugarBEAT system in Europe. The company anticipates a launch in Europe during 2016, pending obtaining requisite product approvals, for which the operational aspects of the launch will be entirely managed by DBJ Jersey under the terms of the agreement, with product support from Nemaura Medical.

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES